<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871011</url>
  </required_header>
  <id_info>
    <org_study_id>SAN-CPT-01</org_study_id>
    <nct_id>NCT02871011</nct_id>
  </id_info>
  <brief_title>Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot</brief_title>
  <official_title>A Blinded Placebo Controlled Clinical Trial To Evaluate Fungicidal Activity With The Topical Application Of Nitric Oxide Releasing Solution (Nors) In Subjects With Moderate To Severe Tinea Pedis (Athlete's Foot)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nitric Solutions Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nitric Solutions Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the fungicidal efficacy of nitric oxide releasing
      solution footbath and it's effect on the clinical signs and symptoms associated with Tinea
      Pedis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: Allocation: Randomized Endpoint Classification:
      Efficacy Study Intervention Model: Sequential Assignment Masking: Double Blind (Subject &amp;
      Assessor) Primary Purpose: Treatment
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2016</start_date>
  <completion_date type="Actual">February 21, 2017</completion_date>
  <primary_completion_date type="Actual">November 14, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete Cure: Post Treatment (Day 17)</measure>
    <time_frame>Day 17</time_frame>
    <description>Complete cure will be determined by negative fungal culture or negative microscopic evaluation via KOH preparation and a Clinical Symptom Severity Score of ≤ 8 (0-64) on Day 17. Improvement is expressed as a lower score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Complete Cure: Post Treatment (Day 31)</measure>
    <time_frame>Day 31</time_frame>
    <description>Complete cure will be determined by a minimum of a 12- point reduction on day 17 in the Clinical Symptom Severity Score (from &gt;20 to &lt;8) on a scale of 0-64. Improvement is expressed as a lower score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Therapeutic Failure: Post Treatment (Day 17)</measure>
    <time_frame>Day 17</time_frame>
    <description>Positive fungi colonization via mycological culture OR microscopic evaluation (KOH) AND a post treatment Clinical Symptom Severity Score of ≤ 8 (0-64) on Day 17. Improvement is expressed as a lower score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants withTherapeutic Failure: Post Treatment Day 31 AND a Post Treatment Clinical Symptom Severity Score (Day 31) of &lt; 8.</measure>
    <time_frame>Day 31</time_frame>
    <description>Positive fungi colonization via mycological culture OR microscopic evaluation (KOH) AND a post treatment Clinical Symptom Severity Score of ≤ 8 (0-64) on Day 31. Improvement is expressed as a lower score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Duration of the study, 31 days for each participant.</time_frame>
    <description>Number of moderate A/E possibly related to treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Participants Clinical Symptom Severity Score Between Day 1 and Day 31</measure>
    <time_frame>Day 1 and 31</time_frame>
    <description>Clinical Symptom Severity Score change in score on Day and Day 31 between all participants with an initial Clinical Symptom severity Score of &gt;20 (0-64 scale) in the two study groups.
Increased improvement is expressed as largest negative change and a lower score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitric oxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide</intervention_name>
    <description>Delivered as a footbath</description>
    <arm_group_label>Nitric oxide</arm_group_label>
    <other_name>NORS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Water</intervention_name>
    <description>Delivered as a footbath</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive clinical findings for moccasin, interdigital or bullous tinea pedis as
             determined by direct clinical examination

          -  Must have a clinical symptom severity score of at least 20 on a possible 64 point
             scale

          -  Written informed consent must be obtained from the subject.

          -  Must ≥ 19 years of age, for study sites located in British Columbia. For other
             locations the subject must be ≥ 18 years of age, unless local laws dictate otherwise.

          -  Must agree to avoid professional pedicures or application of any nail polish product
             or nail cosmetic to the toenails after the screening visit until the conclusion of the
             trial.

          -  Must agree to take measures to avoid pregnancy during the 31 day study period

        Exclusion Criteria:

          -  Has a diagnosis of either psoriasis or eczema, in or immediately around the area under
             evaluation.

          -  Has a visual diagnosis, by the investigator, of onychomycosis at a level, which in the
             opinion of the investigator could compromise the integrity of the study.

          -  Use of topical antifungals e.g. (clotrimazole, ketoconazole,miconazole, oxiconazole-
             (Oxistat®, Glaxo Smith Kline), sulconazole, naftifine (Naftin®, Merz), terconazole,
             econazole nitrate (Spectazole®, Ortho-McNeil), butoconazole ,Fluconazole, ciclopirox
             olamine-(Loprox®), tolnaftate, haloprogin), Zeasorb, antibacterials and
             corticosteroids in the preceding 5 days of screening visit (Day 1) on or immediately
             around the area under evaluation.

          -  Use of systemic corticosteroids in the preceding 7 days respectively, of screening
             visit (Day 1)

          -  Use of systemic antifungals in the preceding 7 days of screening visit (Day1)
             including - (terbinafine - (Lamisil®, Novartis), Itraconazole - (Sporanox®, Janssen),
             fluconazole- (Diflucan®, Pfizer), ketoconazole, miconazole, griseofulvin (GrisPEG®),
             butoconazole, terconazole, Potassium iodide)

          -  Has used any investigational drug(s) within 30 days preceding screening visit (Day 1)

          -  Is pregnant or is a nursing mother

          -  Is a woman of child bearing potential who is not using an adequate form of
             contraception (or abstinence)

          -  Is &lt; 19 years of age, for study sites located in British Columbia. For other locations
             subject is &lt; 18 years of age, unless local laws dictate otherwise.

          -  Suffers from a condition, which, in the opinion of the medical investigator, would
             compromise his/her safety and / or the quality of the data. Such conditions may
             include collagen vascular disease, diabetes mellitus, Cushing's Disease, hematological
             malignancy, chronic mucocutaneous candidiasis or atopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Miller, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nitric Solutions Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fairmont Medical Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z-16H</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <results_first_submitted>October 11, 2018</results_first_submitted>
  <results_first_submitted_qc>August 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2019</results_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tinea Bronchodilator Agents</keyword>
  <keyword>Tinea Pedis</keyword>
  <keyword>Nitric Oxide</keyword>
  <keyword>Dermatomycoses</keyword>
  <keyword>Endothelium-Dependent Relaxing Factors</keyword>
  <keyword>Infectious</keyword>
  <keyword>Infection</keyword>
  <keyword>Mycoses</keyword>
  <keyword>Skin Diseases</keyword>
  <keyword>Foot Dermatoses</keyword>
  <keyword>Foot Diseases</keyword>
  <keyword>Pruritus</keyword>
  <keyword>Skin Manifestations Signs and Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Water: Delivered as a footbath</description>
        </group>
        <group group_id="P2">
          <title>Nitric Oxide</title>
          <description>Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Nitric Oxide: Delivered as a footbath</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Water: Delivered as a footbath</description>
        </group>
        <group group_id="B2">
          <title>Nitric Oxide</title>
          <description>Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Nitric Oxide: Delivered as a footbath</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Randomized Treatment to Control of 2:1</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.1" lower_limit="35" upper_limit="79"/>
                    <measurement group_id="B2" value="53.2" lower_limit="34" upper_limit="79"/>
                    <measurement group_id="B3" value="53.2" lower_limit="34" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Cure: Post Treatment (Day 17)</title>
        <description>Complete cure will be determined by negative fungal culture or negative microscopic evaluation via KOH preparation and a Clinical Symptom Severity Score of ≤ 8 (0-64) on Day 17. Improvement is expressed as a lower score.</description>
        <time_frame>Day 17</time_frame>
        <population>Intent to treat enrollment was 20 individuals but per protocol only a total of 12 participants met the criteria for both a positive fungal culture and microscopic evaluation at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Water: Delivered as a footbath</description>
          </group>
          <group group_id="O2">
            <title>Nitric Oxide</title>
            <description>Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Nitric Oxide: Delivered as a footbath</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Cure: Post Treatment (Day 17)</title>
          <description>Complete cure will be determined by negative fungal culture or negative microscopic evaluation via KOH preparation and a Clinical Symptom Severity Score of ≤ 8 (0-64) on Day 17. Improvement is expressed as a lower score.</description>
          <population>Intent to treat enrollment was 20 individuals but per protocol only a total of 12 participants met the criteria for both a positive fungal culture and microscopic evaluation at baseline.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Cure: Post Treatment (Day 31)</title>
        <description>Complete cure will be determined by a minimum of a 12- point reduction on day 17 in the Clinical Symptom Severity Score (from &gt;20 to &lt;8) on a scale of 0-64. Improvement is expressed as a lower score.</description>
        <time_frame>Day 31</time_frame>
        <population>Intent to treat enrollment was 20 individuals but per protocol only a total of 12 participants met the criteria for both a positive fungal culture and microscopic evaluation at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Water: Delivered as a footbath</description>
          </group>
          <group group_id="O2">
            <title>Nitric Oxide</title>
            <description>Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Nitric Oxide: Delivered as a footbath</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Cure: Post Treatment (Day 31)</title>
          <description>Complete cure will be determined by a minimum of a 12- point reduction on day 17 in the Clinical Symptom Severity Score (from &gt;20 to &lt;8) on a scale of 0-64. Improvement is expressed as a lower score.</description>
          <population>Intent to treat enrollment was 20 individuals but per protocol only a total of 12 participants met the criteria for both a positive fungal culture and microscopic evaluation at baseline.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Therapeutic Failure: Post Treatment (Day 17)</title>
        <description>Positive fungi colonization via mycological culture OR microscopic evaluation (KOH) AND a post treatment Clinical Symptom Severity Score of ≤ 8 (0-64) on Day 17. Improvement is expressed as a lower score.</description>
        <time_frame>Day 17</time_frame>
        <population>Intent to treat enrollment was 20 individuals but per protocol only a total of 12 participants met the criteria for both a positive fungal culture and microscopic evaluation at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Water: Delivered as a footbath</description>
          </group>
          <group group_id="O2">
            <title>Nitric Oxide</title>
            <description>Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Nitric Oxide: Delivered as a footbath</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Therapeutic Failure: Post Treatment (Day 17)</title>
          <description>Positive fungi colonization via mycological culture OR microscopic evaluation (KOH) AND a post treatment Clinical Symptom Severity Score of ≤ 8 (0-64) on Day 17. Improvement is expressed as a lower score.</description>
          <population>Intent to treat enrollment was 20 individuals but per protocol only a total of 12 participants met the criteria for both a positive fungal culture and microscopic evaluation at baseline.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants withTherapeutic Failure: Post Treatment Day 31 AND a Post Treatment Clinical Symptom Severity Score (Day 31) of &lt; 8.</title>
        <description>Positive fungi colonization via mycological culture OR microscopic evaluation (KOH) AND a post treatment Clinical Symptom Severity Score of ≤ 8 (0-64) on Day 31. Improvement is expressed as a lower score.</description>
        <time_frame>Day 31</time_frame>
        <population>Intent to treat enrollment was 20 individuals but per protocol only a total of 12 participants met the criteria for both a positive fungal culture and microscopic evaluation at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Water: Delivered as a footbath</description>
          </group>
          <group group_id="O2">
            <title>Nitric Oxide</title>
            <description>Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Nitric Oxide: Delivered as a footbath</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants withTherapeutic Failure: Post Treatment Day 31 AND a Post Treatment Clinical Symptom Severity Score (Day 31) of &lt; 8.</title>
          <description>Positive fungi colonization via mycological culture OR microscopic evaluation (KOH) AND a post treatment Clinical Symptom Severity Score of ≤ 8 (0-64) on Day 31. Improvement is expressed as a lower score.</description>
          <population>Intent to treat enrollment was 20 individuals but per protocol only a total of 12 participants met the criteria for both a positive fungal culture and microscopic evaluation at baseline.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events</title>
        <description>Number of moderate A/E possibly related to treatment</description>
        <time_frame>Duration of the study, 31 days for each participant.</time_frame>
        <population>Intent to treat enrollment was 20 individuals.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Water: Delivered as a footbath</description>
          </group>
          <group group_id="O2">
            <title>Nitric Oxide</title>
            <description>Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Nitric Oxide: Delivered as a footbath</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Number of moderate A/E possibly related to treatment</description>
          <population>Intent to treat enrollment was 20 individuals.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Participants Clinical Symptom Severity Score Between Day 1 and Day 31</title>
        <description>Clinical Symptom Severity Score change in score on Day and Day 31 between all participants with an initial Clinical Symptom severity Score of &gt;20 (0-64 scale) in the two study groups.
Increased improvement is expressed as largest negative change and a lower score.</description>
        <time_frame>Day 1 and 31</time_frame>
        <population>Intent to treat enrollment was 20 individuals.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Water: Delivered as a footbath</description>
          </group>
          <group group_id="O2">
            <title>Nitric Oxide</title>
            <description>Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Nitric Oxide: Delivered as a footbath</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Participants Clinical Symptom Severity Score Between Day 1 and Day 31</title>
          <description>Clinical Symptom Severity Score change in score on Day and Day 31 between all participants with an initial Clinical Symptom severity Score of &gt;20 (0-64 scale) in the two study groups.
Increased improvement is expressed as largest negative change and a lower score.</description>
          <population>Intent to treat enrollment was 20 individuals.</population>
          <units>Clinial symptom Severity Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="8.6"/>
                    <measurement group_id="O2" value="-18.8" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Thirty-one Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Water: Delivered as a footbath</description>
        </group>
        <group group_id="E2">
          <title>Nitric Oxide</title>
          <description>Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
Nitric Oxide: Delivered as a footbath</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort -warm/sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Chris Miller</name_or_title>
      <organization>SaNOtize Research &amp; Development Corp.</organization>
      <phone>778-899-0607</phone>
      <email>chris@sanotize.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

